Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMMX NASDAQ:OVID NASDAQ:QTTB NASDAQ:STTK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMMXImmix Biopharma$8.84+0.7%$9.41$1.87▼$11.61$477.73M0.121.07 million shs3.65 million shsOVIDOvid Therapeutics$2.45-0.8%$2.56$0.27▼$3.11$461.00M0.181.73 million shs1.09 million shsQTTBQ32 Bio$7.09+22.2%$6.03$1.35▼$8.05$120.22M-0.05243,968 shs297,691 shsSTTKShattuck Labs$6.11+0.2%$6.67$0.71▼$8.33$467.75M1.18557,529 shs440,088 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMMXImmix Biopharma+0.68%-0.56%-10.25%+1.03%+344.22%OVIDOvid Therapeutics-0.81%+2.08%-5.77%+51.23%+758.75%QTTBQ32 Bio+22.24%+16.80%+13.99%+49.89%+337.65%STTKShattuck Labs+0.16%+5.53%-21.06%+50.86%+465.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMMXImmix Biopharma$8.84+0.7%$9.41$1.87▼$11.61$477.73M0.121.07 million shs3.65 million shsOVIDOvid Therapeutics$2.45-0.8%$2.56$0.27▼$3.11$461.00M0.181.73 million shs1.09 million shsQTTBQ32 Bio$7.09+22.2%$6.03$1.35▼$8.05$120.22M-0.05243,968 shs297,691 shsSTTKShattuck Labs$6.11+0.2%$6.67$0.71▼$8.33$467.75M1.18557,529 shs440,088 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMMXImmix Biopharma+0.68%-0.56%-10.25%+1.03%+344.22%OVIDOvid Therapeutics-0.81%+2.08%-5.77%+51.23%+758.75%QTTBQ32 Bio+22.24%+16.80%+13.99%+49.89%+337.65%STTKShattuck Labs+0.16%+5.53%-21.06%+50.86%+465.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMMXImmix Biopharma 2.50Moderate Buy$19.50120.59% UpsideOVIDOvid Therapeutics 2.89Moderate Buy$5.13109.18% UpsideQTTBQ32 Bio 2.60Moderate Buy$13.5090.41% UpsideSTTKShattuck Labs 2.67Moderate Buy$13.00112.77% UpsideCurrent Analyst Ratings BreakdownLatest QTTB, IMMX, STTK, and OVID Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026IMMXImmix Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.005/22/2026QTTBQ32 Bio MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$14.005/22/2026QTTBQ32 Bio MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$14.005/19/2026STTKShattuck Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026QTTBQ32 Bio Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight5/18/2026QTTBQ32 Bio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/14/2026OVIDOvid Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.005/11/2026QTTBQ32 Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)5/8/2026STTKShattuck Labs WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$8.00 ➝ $11.005/5/2026QTTBQ32 Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.004/27/2026STTKShattuck Labs Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight(Data available from 5/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMMXImmix BiopharmaN/AN/AN/AN/A$1.55 per shareN/AOVIDOvid Therapeutics$7.12M64.20N/AN/A$1.06 per share2.31QTTBQ32 Bio$53.74M2.24$1.85 per share3.83$2.73 per share2.60STTKShattuck Labs$1M468.52N/AN/A$1.25 per share4.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMMXImmix Biopharma-$29.44M-$0.92N/AN/AN/AN/A-73.24%-59.20%6/3/2026 (Estimated)OVIDOvid Therapeutics-$17.41M-$0.29N/AN/AN/A-240.11%-22.51%-18.67%8/12/2026 (Estimated)QTTBQ32 Bio$29.82M$2.662.67N/AN/AN/A149.23%34.50%8/5/2026 (Estimated)STTKShattuck Labs-$48.81M-$0.63N/AN/AN/AN/A-60.73%-55.75%8/13/2026 (Estimated)Latest QTTB, IMMX, STTK, and OVID EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026Q1 2026IMMXImmix Biopharma-$0.2084N/AN/AN/AN/AN/A5/12/2026Q1 2026OVIDOvid Therapeutics-$0.12-$0.12N/A-$0.12$0.06 millionN/A5/7/2026Q1 2026IMMXImmix Biopharma-$0.1909-$0.18+$0.0109-$0.18N/AN/A5/7/2026Q1 2026STTKShattuck Labs-$0.14-$0.13+$0.01-$0.13N/AN/A5/5/2026Q1 2026QTTBQ32 Bio-$0.68-$0.54+$0.14-$0.54$39.74 millionN/A3/25/2026Q4 2025IMMXImmix Biopharma-$0.16-$0.28-$0.12-$0.28N/AN/A3/18/2026Q4 2025OVIDOvid Therapeutics-$0.10$0.06+$0.16$0.06$0.06 million$0.72 million3/10/2026Q4 2025QTTBQ32 Bio-$1.06$3.65+$4.71$4.58N/A$53.74 million3/5/2026Q4 2025STTKShattuck Labs-$0.12-$0.12N/A-$0.12$0.17 million($1.00) millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMMXImmix BiopharmaN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/AQTTBQ32 BioN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMMXImmix BiopharmaN/A8.758.75OVIDOvid Therapeutics0.0610.1710.17QTTBQ32 Bio0.045.365.36STTKShattuck LabsN/A22.0722.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMMXImmix Biopharma11.26%OVIDOvid Therapeutics72.24%QTTBQ32 Bio31.32%STTKShattuck Labs58.74%Insider OwnershipCompanyInsider OwnershipIMMXImmix Biopharma30.30%OVIDOvid Therapeutics13.10%QTTBQ32 Bio40.00%STTKShattuck Labs8.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMMXImmix Biopharma954.41 million37.92 millionOptionableOVIDOvid Therapeutics60186.64 million162.19 millionOptionableQTTBQ32 Bio3916.96 million10.17 millionN/ASTTKShattuck Labs10076.68 million69.94 millionOptionableQTTB, IMMX, STTK, and OVID HeadlinesRecent News About These CompaniesShattuck Labs (NASDAQ:STTK) Cut to Hold at Wall Street ZenMay 23, 2026 | americanbankingnews.comShattuck Labs: Priced As If Risk Was Not A Part Of The EquationMay 22, 2026 | seekingalpha.comShattuck Labs (NASDAQ:STTK) Insider Sells $14,244.32 in StockMay 15, 2026 | insidertrades.comWe're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn RateMay 11, 2026 | finance.yahoo.comShattuck Labs (NASDAQ:STTK) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPSMay 8, 2026 | marketbeat.comWedbush Forecasts Strong Price Appreciation for Shattuck Labs (NASDAQ:STTK) StockMay 8, 2026 | marketbeat.comShattuck Labs, Inc.: Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business HighlightsMay 7, 2026 | finanznachrichten.deShattuck Labs Reports First Quarter 2026 Financial Results and Recent Business HighlightsMay 7, 2026 | globenewswire.comCantor Fitzgerald Initiates Coverage of Shattuck Labs (STTK)May 1, 2026 | insidermonkey.comShattuck Labs (STTK) to Release Earnings on ThursdayApril 30, 2026 | marketbeat.comShattuck Labs (STTK) price target increased by 24.00% to 12.65April 29, 2026 | msn.comCantor Fitzgerald initiates coverage of Shattuck Labs (STTK) with overweight recommendationApril 28, 2026 | msn.comShattuck Labs, Inc. (NASDAQ:STTK) Receives Average Recommendation of "Moderate Buy" from AnalystsApril 28, 2026 | marketbeat.comShattuck Labs (NASDAQ:STTK) Coverage Initiated by Analysts at Cantor FitzgeraldApril 27, 2026 | marketbeat.comShattuck Labs: Surviving In An AI World Is Going To Be ToughMarch 27, 2026 | seekingalpha.comShattuck Labs (STTK) price target increased by 37.93% to 10.20March 27, 2026 | msn.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Shattuck Labs (STTK), Oruka Therapeutics (ORKA) and Option Care Health (OPCH)March 14, 2026 | theglobeandmail.comShattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business ...March 5, 2026 | caledonianrecord.comCShattuck Labs Advances SL-325 Clinical Trials, Reports Financial Results for Q4 and Full Year 2025March 5, 2026 | quiverquant.comQShattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business HighlightsMarch 5, 2026 | globenewswire.comShattuck Labs Announces Participation in Upcoming March Investor ConferencesFebruary 25, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQTTB, IMMX, STTK, and OVID Company DescriptionsImmix Biopharma NASDAQ:IMMX$8.84 +0.06 (+0.68%) Closing price 05/26/2026 04:00 PM EasternExtended Trading$8.98 +0.14 (+1.53%) As of 08:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Ovid Therapeutics NASDAQ:OVID$2.45 -0.02 (-0.81%) Closing price 05/26/2026 04:00 PM EasternExtended Trading$2.46 +0.01 (+0.37%) As of 08:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.Q32 Bio NASDAQ:QTTB$7.09 +1.29 (+22.24%) Closing price 05/26/2026 04:00 PM EasternExtended Trading$8.80 +1.71 (+24.12%) As of 08:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.Shattuck Labs NASDAQ:STTK$6.11 +0.01 (+0.16%) Closing price 05/26/2026 04:00 PM EasternExtended Trading$6.13 +0.02 (+0.29%) As of 08:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AutoZone's Pullback Sets Up a Long-Term Buying Opportunity AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus Powerhouse Williams-Sonoma Heading to Fresh Highs in 2026 Quantum Stocks Just Got a Lifeline—Who Benefits Most? Why BJ’s Wholesale Club Stock Could Be Ready for a Rebound 5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade Rocket Companies Turns Around, But Mortgage Risk Remains After NVIDIA, Broadcom's Earnings Are Next—Here's What to Watch Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
